Tackling Neurodegenerative Diseases Through New Initiatives
Pipeline and Therapeutic proof of concept
Compatible therapeutics include small molecules, gene-silencing therapies such as siRNAs and ASOs, as well as other macromolecules such as antibodies, peptides, other oligonucleotides, etc.
The OCCT platform can shuttle both noncovalently-bound or covalently-bound cargoes to the brain.
The OCCT platform can target a diverse range of neurological indication.